A naukri.com initiative
Bloomberg Quint
4d
78
Image Credit: Bloomberg Quint
Natco Pharma Q4 Results Review: Dolat Capital Maintains 'Sell', Sees 11% Downside
- Dolat Capital maintains 'Sell' rating for Natco Pharma with a revised target price of Rs772 at 28x FY27E P/E.
- Natco Pharma's exports grew by 10.2% YoY in Q4 FY25, showing lower growth compared to earlier quarters despite higher gRevlimid sales.
- The brokerage believes Natco is facing challenges in base business growth ex Revlimid, leading to significant erosion of core margins.
Read Full Article
4 Likes
For uninterrupted reading, download the app